Raloxifene Tablets
designed to support bone density, utilized to mitigate the risk of fractures in postmenopausal women by targeting oestrogen pathways.
Strengths: 60mg
Where to Check Availability
Medicine details
- Conditions
- Alternative names
Evista
- Therapeutic class
Selective oestrogen Receptor Modulator
- Pharmacological class
SERM
- Precautions and warnings
discontinue before prolonged immobilisation; monitor for signs of blood clots
- Minor side effects
hot flushes; leg cramps
- Moderate side effects
peripheral oedema; flu-like symptoms
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Daiichi Sankyo
- Onset Time
3–6 months
- Duration
Ongoing
- Storage instructions
Store in a cool, dry place.
- Drug interactions
warfarin; cholestyramine
- Age restrictions
Limited to postmenopausal women.
Contraindications
history of venous thromboembolism; hepatic impairment; severe renal impairment; uterine bleeding; pregnancy
Serious side effects
deep vein thrombosis — requires immediate medical attention; pulmonary embolism — requires immediate medical attention; stroke — requires immediate medical attention
Patient summary
designed to support bone density, utilized to mitigate the risk of fractures in postmenopausal women by targeting oestrogen pathways.
Mechanism of action
A selective oestrogen receptor modulator that mimics the beneficial effects of oestrogen on bone tissue while inhibiting its effects on breast and uterine tissue.
Pregnancy and breastfeeding
Pregnancy: Contraindicated; may cause harm to the foetus. Breastfeeding: Not applicable.
Raloxifene Tablets
designed to support bone density, utilized to mitigate the risk of fractures in postmenopausal women by targeting oestrogen pathways.
Editorial Notes
- Active ingredient(s): Raloxifene
- Listed indication(s): Osteoporosis
Available option
- 60 tablets - 60 mg1246-60-mg-14870